In the past decade, immunotherapies have become an increasingly promising way of combatting cancer. Most of them work by hijacking the body’s immune system and employing it to fight disease. But one treatment has arguably shown the most promise. Originally known as CAR T-cell immunotherapy, two brands of the treatment were recently approved by the FDA: Novartis’ Kymriah and Kite Pharma’s Yescarta. The treatment is arguably the most precise and potentially curative to date, and is the first available human gene therapy for cancer. Now, in two studies out today in the New England Journal of Medicine, researchers report the therapy’s success in treating a type of lymphoma.
The studies, which were used to help the treatments gain FDA approval, show that this type of therapy can be highly effective in a variety of hospital and clinical settings around the world. And by comparing individuals who don’t respond to ones who …
READ MORE ON POPSCI.COM